Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Johnson and Johnson
Colorcon
Dow
Harvard Business School

Last Updated: August 10, 2022

Litigation Details for BURLINGTON DRUG CO., INC. v. PFIZER INC. (D.N.J. 2012)


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Small Molecule Drugs cited in BURLINGTON DRUG CO., INC. v. PFIZER INC.
The small molecule drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .

Details for BURLINGTON DRUG CO., INC. v. PFIZER INC. (D.N.J. 2012)

Date Filed Document No. Description Snippet Link To Document
2013-09-05 455 Order on Motion to Dismiss Reissue Patent No. 40,667 (the “RE ‘667 patent’”)); U.S. Patent No. 6,126,971 (the “‘971 patent”); U.S….S. Patent No. 5,686,104 (the “‘104 patent”); U.S. Patent No. 6,087,511 (the “‘511 patent”); U.S. Patent… Patent No. 6,274,740 (the “‘740 patent”); and U.S. Patent No. 5,969,156 (the “‘156 patent”). See, …4,681,893 (the “‘893 patent”); U.S. Patent No. 5,273,995 (the “‘995 patent,” reissued in part as U.S. Reissue…particular Lipitor Patent – the ‘995 patent – as well as its relationship to the ‘893 patent. Compl. ¶¶ External link to document
2014-09-12 566 Memorandum Reissue Patent No. 40,667); U.S. Patent No. 6,126,971 (the “‘971 patent”); U.S. Patent No. 5,686,104 (the…the “‘104 patent”); U.S. Patent No. 6,087,511 (the “‘511 patent”); U.S. Patent No. 6,274,740 (the “…back up” patents — the ‘156 patent, the two Formulation Patents (the ‘971 and ‘104 patents), and the…exclusive licensee of the ’995 patent and other patents (need full cite of patent). At all relevant times…4,681,893 (the “‘893 patent”); U.S. Patent No. 5,273,995 (the “‘995 patent,” reissued later as U.S. Reissue External link to document
2018-08-17 812 Letter 6,503,894 ("'894 patent") for a brand-name testosterone…the ’122 patent”); Patent No. 8,329,216 (“the ’216 patent”); Patent No. 8,808,737 (“the ’737 patent…the ’250 patent”), 5,662,933 (“the ’933 patent”), and 5,958,456 (“the ’456 patent”) (“the…proposed broadening the patent license in the SLA to “any patents and patent applications owned… the patent[s], not just the patent [at issue] today, but cover all future patent[s] as External link to document
2018-09-20 815 Amended Complaint following patents in the Orange Book as covering Lipitor: 6,126,971 (the “’971 Patent”); 5,686,1046,126,971 (the “’971 Patent,” expiry November 11, 2014). Both the ’104 and ’971 Patents cover …follow-on patent (U.S. Patent Number 5,273,995, the “’995 Enantiomer Patent” or the “’995 Patent” or the… and patent applicant of both the ’893 Patent and the duplicative follow-on patent. Both patents issued…Stabilization Formulation Patents, the ’156 Patent, the ’995 Patent, and ’667 Patent), baseless sham litigation External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Medtronic
AstraZeneca
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.